Navigation Links
Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3
Date:5/11/2009

FREMONT, Calif., May 11 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, presented a study titled, "PF-04523655 (REDD14NP), an siRNA Compound Targeting RTP801, Penetrates Retinal Cells Producing Target Gene Knockdown and Avoiding TLR3 Activation," at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place from May 3-7, 2009, in Fort Lauderdale, Florida. PF-04523655 is currently being studied by partners Pfizer and Quark in patients with diabetic macular edema (DME) and age-related macular degeneration (AMD).

The study presented at ARVO was performed in collaboration with Dr. Jayakrishna Ambati at the Department of Ophthalmology and Visual Sciences, University of Kentucky College of Medicine, Lexington, KY. The objective of the study was to determine whether PF-04523655, a synthetic chemically modified 19-bp siRNA, enters cells in the retina leading to downregulation of its target gene while avoiding activation of Toll Like Receptor 3 (TLR3). Previous studies from Dr. Ambati's laboratory have shown that unmodified 21-mer siRNA molecules exhibit antiangiogenic effects by inadvertently activating TLR3 rather than down-regulating expression of their target genes. Results obtained in vivo and in vitro indicated that PF-04523655 does enter cells in the retina and elicits its pharmacologic effect via target gene knock-down without activating TLR3.

Daniel Zurr, Ph.D., President and Chief Executive Officer, said, "We believe that the results presented at ARVO continue to substantiate our leadership in siRNA therapeutics, in particular Quark's ability to develop highly specific siRNA products and advance them through the clinic toward commercialization. Quark's ability to establish col
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
2. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
3. Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
4. Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
11. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... 2014 Cirrascale Corporation ®, ... and rackmount computing infrastructure, today announced it will ... throughout its GPU-enabled blade server and high-performance workstation ... latest proprietary 80-lane Gen3 PCIe switch-enabled risers, the ... K80 dual-GPU accelerator cards in a single blade, ...
(Date:11/18/2014)... 18, 2014 American Process Inc. ... formed a partnership with researchers at Georgia Institute ... Technology, and the USDA’s Forest Products Laboratory to ... nanocellulose. Nanocellulose is a rapidly emerging high performance ... project is to replace heavy steel structures within ...
(Date:11/18/2014)... Nov. 18, 2014 PDL BioPharma, Inc. (PDL) ... connection with the acquisition of Durata Therapeutics, Inc. by ... with the termination of PDL,s credit agreement with Durata, ... of $40 million, accrued interest, and prepayment and change ... a structured financing transaction with Durata in which PDL ...
(Date:11/17/2014)... The new METTLER TOLEDO White Paper " Traceability ... becoming the first calibration laboratory in the world ... the microgram range. National Metrology Institutes (NMI's), private ... in nanotechnology applications will benefit from understanding the ... weights in the range of 0.05 mg to ...
Breaking Biology Technology:Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 3PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2New White Paper on Microgram Weights Describes How to Achieve Traceable Measurement Down to 0.05 Milligrams 2
... Jan. 31, 2011 Fox Chase Cancer Center , one ... the posting of clinical outcomes data to its website ... seek cancer care.  This initiative follows on a survey Fox Chase ... success rates as the factor that would be the most ...
... China-Biotics, Inc. ("China-Biotics", the "Company") (Nasdaq: ... of probiotics products in China, today announced it will ... p.m. Beijing Time on Wednesday, February 9, 2011, to ... for the period ended December 31, 2010. ...
... Mass., Jan. 31, 2011 Haemonetics Corporation (NYSE: HAE ... net income of $19.7 million, up 8%, and earnings per share ... third quarter net income was $ 22.6 million, up 21%, and ... revenue was up 6%, adjusted net income was up 21%, and ...
Cached Biology Technology:Fox Chase Cancer Center Publishes Clinical Outcomes for Patient Use 2Fox Chase Cancer Center Publishes Clinical Outcomes for Patient Use 3China-Biotics to Report Fiscal Year 2011 Third Quarter Financial Results on February 9 2Haemonetics Reports Third Quarter of Fiscal 11 2Haemonetics Reports Third Quarter of Fiscal 11 3Haemonetics Reports Third Quarter of Fiscal 11 4Haemonetics Reports Third Quarter of Fiscal 11 5Haemonetics Reports Third Quarter of Fiscal 11 6Haemonetics Reports Third Quarter of Fiscal 11 7Haemonetics Reports Third Quarter of Fiscal 11 8Haemonetics Reports Third Quarter of Fiscal 11 9Haemonetics Reports Third Quarter of Fiscal 11 10Haemonetics Reports Third Quarter of Fiscal 11 11Haemonetics Reports Third Quarter of Fiscal 11 12Haemonetics Reports Third Quarter of Fiscal 11 13
(Date:11/6/2014)... Baltimore, MD, November 6, 2014 - Insilico Medicine, ... in aging and age related diseases announced a ... medicine of cancer, Champions Oncology, Inc (OTC: CSBR). ... genomics for personalized medicine, but Champions Oncology,s TumorGraft ... can validate the chemotherapy regimen experimentally generating vast ...
(Date:11/5/2014)... RENO – Kelly Redmond has dedicated his career ... knowledge to a general audience. , As deputy ... Climate Center at Nevada,s Desert Research Institute, Redmond ... the management, application and dissemination of climate data ... Annual Fall Meeting in San Francisco on December ...
(Date:11/4/2014)... SALT LAKE CITY, Nov. 5, 2014 – University of ... uses enzymes to help jet fuel produce electricity without ... can be used to power portable electronics, off-grid power ... appears online today in the American Chemical Society journal ... into electricity through a chemical reaction between a fuel ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2Jet-fueled electricity at room temperature 2
... 2012 The Phoenix Community Alliance (PCA) will honor ... Institute (TGen), with its most prestigious award. Dr. ... Award for his work in improving the lives of ... such as Alzheimer,s, diabetes and many types of cancer. ...
... The National Institutes of Health has awarded The Scripps ... pathway in the development and maintenance of B-cell lymphoma, a ... normal disease fighting cells into cancers. The disease affects immune ... blood cells. John Cleveland, PhD, chair of the ...
... MD FASEB MARC (Maximizing Access to Research Careers) ... 2012 American Society for Clinical Investigation/Association of American Physicians ... 2012. These awards are meant to promote the ... the mainstream of the basic science community and to ...
Cached Biology News:Phoenix Community Alliance honors TGen's Dr. Jeffrey Trent 2Scientists win $2 million to study new pathway in development and maintenance of lymphoma 2
... configured specifically for pharmaceutical powder packaging, ... are precision-joined to create ultra-smooth surfaces ... and disinfect. One-inch radius corners simplify ... strong, rigid surface without external bracing. ...
... sensitive reagent for the detection of inorganic ... of recombinant E. coli phosphate-binding protein labeled ... to changes in its environment.How it worksBinding ... rapid and tight (Kd ~ 0.1 M), ...
... This benchtop ductless exhaust hood ... allowing safe indoor release of exhaust. ... contaminants. Over 28" of vertical clearance ... glassware. Includes polypropylene spill tray; options ...
... ideal modular cleanroom for biological safety ... require cleanliness (to Class 10/ISO 3) ... to create ultra-smooth surfaces that are ... One-inch radius corners simplify cleaning. Unique ...
Biology Products: